Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings
About Aurisco Pharmaceutical Co.,Ltd.
Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 国泰海通证券股份有限公司关于奥锐特药业股份有限公司公司2025年度持续督导年度报告书 | 2026-04-16 | Chinese | |
| 奥锐特药业股份有限公司关于公司及子公司向银行及其他融资机构申请综合授信额度的公告 | 2026-04-16 | Chinese | |
| 奥锐特药业股份有限公司2025年度利润分配方案公告 | 2026-04-16 | Chinese | |
| 关于奥锐特药业股份有限公司非经营性资金占用及其他关联资金往来的专项说明 | 2026-04-16 | Chinese | |
| 奥锐特药业股份有限公司董事、高级管理人员薪酬管理制度 | 2026-04-16 | Chinese | |
| 奥锐特药业股份有限公司2025年度审计报告 | 2026-04-16 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 39179886 | 国泰海通证券股份有限公司关于奥锐特药业股份有限公司公司2025年度持续督导年度报告书 | 2026-04-16 | Chinese | ||
| 39179883 | 奥锐特药业股份有限公司关于公司及子公司向银行及其他融资机构申请综合授信额度的公告 | 2026-04-16 | Chinese | ||
| 39179882 | 奥锐特药业股份有限公司2025年度利润分配方案公告 | 2026-04-16 | Chinese | ||
| 39179880 | 关于奥锐特药业股份有限公司非经营性资金占用及其他关联资金往来的专项说明 | 2026-04-16 | Chinese | ||
| 39179875 | 奥锐特药业股份有限公司董事、高级管理人员薪酬管理制度 | 2026-04-16 | Chinese | ||
| 39179874 | 奥锐特药业股份有限公司2025年度审计报告 | 2026-04-16 | Chinese | ||
| 39179868 | 奥锐特药业股份有限公司2025年环境、社会和公司治理（ESG）报告（英文） | 2026-04-16 | Chinese | ||
| 39179860 | 奥锐特药业股份有限公司2025年度独立董事述职报告（陈应春） | 2026-04-16 | Chinese | ||
| 39179859 | 奥锐特药业股份有限公司2025年度董事会审计委员会履职报告 | 2026-04-16 | Chinese | ||
| 39179855 | 奥锐特药业股份有限公司2025年度独立董事述职报告（钟永成） | 2026-04-16 | Chinese | ||
| 39179853 | 奥锐特药业股份有限公司2025年年度报告摘要 | 2026-04-16 | Chinese | ||
| 39179850 | 国泰海通证券股份有限公司关于奥锐特药业股份有限公司2025年度募集资金存放与使用情况的专项核查意见 | 2026-04-16 | Chinese | ||
| 39179849 | 关于奥锐特药业股份有限公司非经营性资金占用及其他关联资金往来情况汇总表的专项审计报告 | 2026-04-16 | Chinese | ||
| 39179848 | 奥锐特药业股份有限公司关于会计政策变更的公告 | 2026-04-16 | Chinese | ||
| 39179839 | 奥锐特药业股份有限公司2025年环境、社会和公司治理（ESG）报告（中文） | 2026-04-16 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
Aurisco Pharmaceutical Co.,Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/57980/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=57980 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=57980 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=57980 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 57980}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Aurisco Pharmaceutical Co.,Ltd. (id: 57980)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.